Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Codexis (CDXS – Research Report) today. The company’s shares closed last Friday at $2.66.
According to TipRanks, Hewitt is an analyst with an average return of -4.0% and a 40.49% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Codexis, and Repligen.
Codexis has an analyst consensus of Strong Buy, with a price target consensus of $6.75, implying a 153.76% upside from current levels. In a report released on April 26, Piper Sandler also assigned a Buy rating to the stock with a $10.00 price target.
The company has a one-year high of $4.91 and a one-year low of $1.45. Currently, Codexis has an average volume of 571.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis (CDXS) Company Description:
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Read More on CDXS:
- Codexis to Report First Quarter 2024 Financial Results on May 2
- Codexis appoints Carole Cobb to strategic advisory board
- Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
- Biotech Alert: Searches spiking for these stocks today
- A New Cause for Concern: Codexis Adds a New Corporate Activity and Growth Risk
